TY - JOUR
T1 - Clinical relevance of molecular markers in neuroblastoma
T2 - results from a single institution.
AU - Gallego, S.
AU - Parareda, A.
AU - Munell, F.
AU - Sanchez de Toledo, J.
AU - Reventos, J.
PY - 1999
Y1 - 1999
N2 - Neuroblastomas, the most common extracranial solid tumors in children, present an extremely heterogeneous behaviour that can be explained in part by their genetic abnormalities. Thirty-four patients treated at the Pediatric Oncology Unit, Hospital Vall d'Hebron from 1993 to 1997 were prospectively studied to determine the relative prognostic impact of a number of clinical and molecular factors. The factors studied were: ploidy, MYCN and 1p status, and TRK-A expression, in addition to age, stage and histology. Their impact on prognosis was analyzed. In univariate analysis, advanced stage, unfavorable histology, diploidy, MYCN amplification, and 1p deletion were identified as adverse prognostic factors; TRK-A expression was associated with favorable prognosis. After multivariate analysis, only MYCN amplification proved to be an independent adverse prognostic factor (p=0.03), whereas TRK-A expression identified a subset of good-prognosis patients (p=0.003).
AB - Neuroblastomas, the most common extracranial solid tumors in children, present an extremely heterogeneous behaviour that can be explained in part by their genetic abnormalities. Thirty-four patients treated at the Pediatric Oncology Unit, Hospital Vall d'Hebron from 1993 to 1997 were prospectively studied to determine the relative prognostic impact of a number of clinical and molecular factors. The factors studied were: ploidy, MYCN and 1p status, and TRK-A expression, in addition to age, stage and histology. Their impact on prognosis was analyzed. In univariate analysis, advanced stage, unfavorable histology, diploidy, MYCN amplification, and 1p deletion were identified as adverse prognostic factors; TRK-A expression was associated with favorable prognosis. After multivariate analysis, only MYCN amplification proved to be an independent adverse prognostic factor (p=0.03), whereas TRK-A expression identified a subset of good-prognosis patients (p=0.003).
UR - http://www.scopus.com/inward/record.url?scp=0033161220&partnerID=8YFLogxK
U2 - 10.3892/or.6.4.891
DO - 10.3892/or.6.4.891
M3 - Artículo
C2 - 10373677
AN - SCOPUS:0033161220
SN - 1021-335X
VL - 6
SP - 891
EP - 896
JO - Oncology Reports
JF - Oncology Reports
IS - 4
ER -
